Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04576091
Title Testing the Addition of an Anti-cancer Drug, BAY1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

hypopharynx cancer

oropharynx cancer

laryngeal squamous cell carcinoma

oral squamous cell carcinoma

head and neck squamous cell carcinoma

Therapies

BAY1895344 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.